Cargando…

Risk-Reducing Options for High-Grade Serous Gynecologic Malignancy in BRCA1/2

Ovarian cancer (OC) is the leading cause of death among women with gynecologic malignancy. Breast Cancer Susceptibility Gene 1 (BRCA 1) and Breast Cancer Susceptibility Gene 2 (BRCA 2) germline mutations confer an estimated 20 to 40 times increased risk of OC when compared to the general population....

Descripción completa

Detalles Bibliográficos
Autores principales:	Clarfield, Lauren, Diamond, Laura, Jacobson, Michelle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946924/ https://www.ncbi.nlm.nih.gov/pubmed/35323372 http://dx.doi.org/10.3390/curroncol29030172

Ejemplares similares

NLR and BRCA mutational status in patients with high grade serous advanced ovarian cancer
por: Marchetti, Claudia, et al.
Publicado: (2021)

Low grade serous carcinoma of the peritoneum in a BRCA1 carrier previously diagnosed with a “low-grade serous tubal intra-epithelial carcinoma” (STIC) on risk reducing surgery
por: Chay, Wen Yee, et al.
Publicado: (2015)

Potent immunogenicity in BRCA1‐mutated patients with high‐grade serous ovarian carcinoma
por: Dai, Ying, et al.
Publicado: (2018)

Single-cell tumor-immune microenvironment of BRCA1/2 mutated high-grade serous ovarian cancer
por: Launonen, I.-M., et al.
Publicado: (2022)

High-Grade Serous Carcinoma at Risk-Reducing Salpingo-Oophorectomy in Asymptomatic Carriers of BRCA1/2 Pathogenic Variants: Prevalence and Clinical Factors
por: Stroot, Iris A.S., et al.
Publicado: (2023)

Tumor BRCA Testing in High Grade Serous Carcinoma: Mutation Rates and Optimal Tissue Requirements
por: Turashvili, Gulisa, et al.
Publicado: (2020)

CCNE1 amplification among metastatic sites in patients with gynecologic high-grade serous carcinoma
por: Margolis, Benjamin, et al.
Publicado: (2021)

Adequacy of risk-reducing gynaecologic surgery in BRCA1 or BRCA2 mutation carriers and other women at high risk of pelvic serous cancer
por: Kiely, B. E., et al.
Publicado: (2011)

Constitutional BRCA1 Methylation and Risk of Incident Triple-Negative Breast Cancer and High-grade Serous Ovarian Cancer
por: Lønning, Per E., et al.
Publicado: (2022)

Enhanced response rate to pegylated liposomal doxorubicin in high grade serous ovarian carcinomas harbouring BRCA1 and BRCA2 aberrations
por: Hollis, Robert L., et al.
Publicado: (2018)

Reversing Platinum Resistance in High-Grade Serous Ovarian Carcinoma: Targeting BRCA and the Homologous Recombination System
por: Wiedemeyer, W. Ruprecht, et al.
Publicado: (2014)

Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer
por: Kim, Se Ik, et al.
Publicado: (2019)

Spectrum of TP53 Mutations in BRCA1/2 Associated High-Grade Serous Ovarian Cancer
por: Boyarskikh, Ulyana A., et al.
Publicado: (2020)

Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer
por: Eoh, Kyung Jin, et al.
Publicado: (2020)

Germline and tumor BRCA1/2 mutations in Chinese high grade serous ovarian cancer patients
por: Ji, Gang, et al.
Publicado: (2021)

PARP Inhibitors Display Differential Efficacy in Models of BRCA Mutant High-Grade Serous Ovarian Cancer
por: Dickson, Kristie-Ann, et al.
Publicado: (2021)

BRCA-2 (+) high-grade serous fallopian tube cancer diagnosed as an isolated breast mass by mammography
por: Sobecki, Janelle N., et al.
Publicado: (2020)

Differential Sensitivity of Germline and Somatic BRCA Variants to PARP Inhibitor in High-Grade Serous Ovarian Cancer
por: Vendrell, Julie A., et al.
Publicado: (2023)

No evidence for PALB2 methylation in high-grade serous ovarian cancer
por: Mikeska, Thomas, et al.
Publicado: (2013)

Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status
por: Gadducci, Angiolo, et al.
Publicado: (2019)

Development of a Bioluminescent BRCA1-Deficient Xenograft Model of Disseminated, High-Grade Serous Ovarian Cancer
por: Shen, Yen Ting, et al.
Publicado: (2019)

Interferon-γ signaling is associated with BRCA1 loss-of-function mutations in high grade serous ovarian cancer
por: Cardenas, Horacio, et al.
Publicado: (2019)

Referral, Genetic Counselling, and BRCA Testing in the Manitoba High-Grade Serous Ovarian Cancer Population, 2004–2019
por: Winchar, Kelcey, et al.
Publicado: (2022)

The Continuum of Serous Tumors of Low Malignant Potential and Low-Grade Serous Carcinomas of the Ovary
por: Wong, Kwong-Kwok, et al.
Publicado: (2007)

Risk-Reducing Breast and Gynecological Surgery for BRCA Mutation Carriers: A Narrative Review
por: Bertozzi, Serena, et al.
Publicado: (2023)

Reflex BRCA1 and BRCA2 tumour genetic testing for high-grade serous ovarian cancer: streamlined for clinicians but what do patients think?
por: McCuaig, Jeanna M., et al.
Publicado: (2022)

The impact of an educational and information systems initiative on somatic BRCA testing rates in patients with high grade serous tubo-ovarian cancer in Western Australia
por: Fantoni, Andrew, et al.
Publicado: (2023)

High EMSY expression defines a BRCA‐like subgroup of high‐grade serous ovarian carcinoma with prolonged survival and hypersensitivity to platinum
por: Hollis, Robert L., et al.
Publicado: (2019)

Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting
por: Dougherty, Brian A., et al.
Publicado: (2017)

Gross genomic alterations and gene expression profiles of high- grade serous carcinoma of the ovary with and without BRCA1 inactivation
por: Pradhan, Manohar, et al.
Publicado: (2010)

High-Grade Serous Tumor Arising from Fallopian Tube in a BRCA Mutation Carrier after Prophylactic Oophorectomy
por: Lorusso, Domenica, et al.
Publicado: (2013)

Concurrent Primary Peritoneal Low-Grade Serous Carcinoma and Endometrial High-Grade Serous Carcinoma
por: Lockyer, Megan G., et al.
Publicado: (2015)

High grade serous ovarian carcinomas originate in the fallopian tube
por: Labidi-Galy, S. Intidhar, et al.
Publicado: (2017)

The Influence of PARP, ATR, CHK1 Inhibitors on Premature Mitotic Entry and Genomic Instability in High-Grade Serous BRCA(MUT) and BRCA(WT) Ovarian Cancer Cells
por: Gralewska, Patrycja, et al.
Publicado: (2022)

MicroRNA Profiling of BRCA1/2 Mutation-Carrying and Non-Mutation-Carrying High-Grade Serous Carcinomas of Ovary
por: Lee, Cheng-Han, et al.
Publicado: (2009)

Vaccinations against human papillomavirus missed because of COVID-19 may lead to a rise in preventable cervical cancer
por: Diamond, Laura M., et al.
Publicado: (2021)

High Throughput Interrogation of Somatic Mutations in High Grade Serous Cancer of the Ovary
por: Matulonis, Ursula A., et al.
Publicado: (2011)

Changes in Nucleolin Expression during Malignant Transformation Leading to Ovarian High-Grade Serous Carcinoma
por: Paris, Elizabeth A., et al.
Publicado: (2023)

Oncogenes in high grade serous adenocarcinoma of the ovary
por: Manasa, Pacharla, et al.
Publicado: (2020)

BRCA1 mutations in high-grade serous ovarian cancer are associated with proteomic changes in DNA repair, splicing, transcription regulation and signaling
por: Bradbury, Melissa, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_006540do3qrh8rpcq9hf3iiruo